Cargando…
Anti-spike antibody response to the COVID vaccine in lymphoma patients
Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714943/ https://www.ncbi.nlm.nih.gov/pubmed/36454941 http://dx.doi.org/10.1371/journal.pone.0266584 |
_version_ | 1784842348429049856 |
---|---|
author | Della Pia, Alexandra Kim, Gee Youn (Geeny) Ip, Andrew Ahn, Jaeil Liu, Yanzhi Kats, Simone Koropsak, Michael Lukasik, Brittany Contractor, Anamta Amin, Krushna Ayyagari, Lakshmi Zhao, Charles Gupta, Amolika Batistick, Mark Leslie, Lori A. Goy, Andre H. Feldman, Tatyana A. |
author_facet | Della Pia, Alexandra Kim, Gee Youn (Geeny) Ip, Andrew Ahn, Jaeil Liu, Yanzhi Kats, Simone Koropsak, Michael Lukasik, Brittany Contractor, Anamta Amin, Krushna Ayyagari, Lakshmi Zhao, Charles Gupta, Amolika Batistick, Mark Leslie, Lori A. Goy, Andre H. Feldman, Tatyana A. |
author_sort | Della Pia, Alexandra |
collection | PubMed |
description | Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody level following the primary COVID vaccination series. The primary vaccination series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate and multivariate analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined; 12 patients (5%) with mantle cell lymphoma; and 4 patients (2%) with other lymphoma types. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary vaccination series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p = 0.04). Lymphoma patients are capable of mounting a humoral response to the COVID vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population. |
format | Online Article Text |
id | pubmed-9714943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-97149432022-12-02 Anti-spike antibody response to the COVID vaccine in lymphoma patients Della Pia, Alexandra Kim, Gee Youn (Geeny) Ip, Andrew Ahn, Jaeil Liu, Yanzhi Kats, Simone Koropsak, Michael Lukasik, Brittany Contractor, Anamta Amin, Krushna Ayyagari, Lakshmi Zhao, Charles Gupta, Amolika Batistick, Mark Leslie, Lori A. Goy, Andre H. Feldman, Tatyana A. PLoS One Research Article Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody level following the primary COVID vaccination series. The primary vaccination series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate and multivariate analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined; 12 patients (5%) with mantle cell lymphoma; and 4 patients (2%) with other lymphoma types. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary vaccination series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p = 0.04). Lymphoma patients are capable of mounting a humoral response to the COVID vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population. Public Library of Science 2022-12-01 /pmc/articles/PMC9714943/ /pubmed/36454941 http://dx.doi.org/10.1371/journal.pone.0266584 Text en © 2022 Della Pia et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Della Pia, Alexandra Kim, Gee Youn (Geeny) Ip, Andrew Ahn, Jaeil Liu, Yanzhi Kats, Simone Koropsak, Michael Lukasik, Brittany Contractor, Anamta Amin, Krushna Ayyagari, Lakshmi Zhao, Charles Gupta, Amolika Batistick, Mark Leslie, Lori A. Goy, Andre H. Feldman, Tatyana A. Anti-spike antibody response to the COVID vaccine in lymphoma patients |
title | Anti-spike antibody response to the COVID vaccine in lymphoma patients |
title_full | Anti-spike antibody response to the COVID vaccine in lymphoma patients |
title_fullStr | Anti-spike antibody response to the COVID vaccine in lymphoma patients |
title_full_unstemmed | Anti-spike antibody response to the COVID vaccine in lymphoma patients |
title_short | Anti-spike antibody response to the COVID vaccine in lymphoma patients |
title_sort | anti-spike antibody response to the covid vaccine in lymphoma patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714943/ https://www.ncbi.nlm.nih.gov/pubmed/36454941 http://dx.doi.org/10.1371/journal.pone.0266584 |
work_keys_str_mv | AT dellapiaalexandra antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT kimgeeyoungeeny antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT ipandrew antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT ahnjaeil antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT liuyanzhi antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT katssimone antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT koropsakmichael antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT lukasikbrittany antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT contractoranamta antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT aminkrushna antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT ayyagarilakshmi antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT zhaocharles antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT guptaamolika antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT batistickmark antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT leslieloria antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT goyandreh antispikeantibodyresponsetothecovidvaccineinlymphomapatients AT feldmantatyanaa antispikeantibodyresponsetothecovidvaccineinlymphomapatients |